The chimeric β1/β2-adrenoceptor constructs
| Amino Acid Changes | |
|---|---|
| β2-WT | |
| β2-N | β2 but with full N terminus of the β1—see Materials and Methods for details |
| β2-EL1 | M96W, K97G, M98R, T100E, F101Y, N103S, W105F |
| β2-EL2 | T177E, H178S, Q179D, I182R, N183R, A186N, N187D, E188P, T189K, F194V |
| β2-EL3 | Q299H, D300R, N301E, I303V, R304P, K305D |
| β2-TM1 | I38L, V39L, S41A, A46L, F49A, T56V |
| β2-TM2 | T73M, C77S, A85L, A92T, H93I, I94V, L95V |
| β2-TM3 | F108L, I112V, V129L |
| β2-TM4a | V152G, I153L, I154V, L155C, M156T, I159A, V160I, G162A, T164V, Q170L |
| β2-TM5 | Q197R, I205V, V213C, V216A, S220L |
| β2-TM6 | T281V, I291L, V292A, I294V, H296K, V297A, I298F |
| β2-TM7 | E306R, V307L, Y308F, I309V, L310F, L311F, I314L, V317A, G320A, L324I |
| β1-WT | |
| β1-N | β1 but with full N terminus of the β2—see Materials and Methods for details |
| β1-EL1 | W121M, G122K, R123M, E125T, Y126F, S128N, F130W |
| β1-EL2 | E202T, S203H, D204Q, R207I, R208N, N211A, D212N, P213E, K214T, V219F |
| β1-EL3 | H350Q, R351D, E352N, V354I, P355R, D356K |
| β1-TM1 | L63I, L64V, A66S, L71A, A74F, V81T |
| β1-TM2 | M98T, S102C, L110A, T117A, I118H, V119I, V120L |
| β1-TM3 | L133F, V137I, L154V |
| β1-TM4 | G177V, L178I, V179I, C180L, T181M, A184I, I185V, A187G, V189T, L195Q, W199Y |
| β1-TM5 | R222Q, V230I, C238V, A241V, L245S |
| β1-TM6 | V332T, L342I, A343V, V345I, K347H, A348V, F349I |
| β1-TM7 | R357E, L358V, F359Y, V360I, F361L, F362L, L365I, A368V, A371G, I375L |
↵a Making the full change here, i.e., with Y174W, rendered the receptor nonfunctional (no binding and no functional responses). This chimera with 10 of the 11 amino acid substitutions was therefore used as the β2-TM4 mutant.